<DOC>
	<DOCNO>NCT01871376</DOCNO>
	<brief_summary>To evaluate efficacy safety intravitreal aflibercept injection treatment PCV</brief_summary>
	<brief_title>Intravitreal Aflibercept Injection Polypoidal Choroidal Vasculopathy With Hemorrhage Exudation</brief_title>
	<detailed_description>This open-label , randomize , one-year , multiple-dose study 2mg aflibercept patient PCV . The study consist baseline visit day 0 mandatory clinic visit every 30 day assess efficacy safety . All patient receive three monthly injection 2mg intravitreal aflibercept injection follow treatment every 60 day 720 day ( 24 month ) . Patients treat every 30 day need . The fellow eye may treat intravitreal aflibercept injection per investigator 's discretion point study evidence disease activity meet : exudation hemorrhage secondary polypoidal choroidal vasculopathy exudative AMD . The fellow eye consider study eye . If treatment aflibercept give fellow eye , injection administer accord Food Drug Administration ( FDA ) approve label EYLEA® .</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Vascular Diseases</mesh_term>
	<criteria>Age &gt; 25 year age . In opinion principal investigator , study eye PCV active exudation and/or bleed may benefit treatment study medication . Diagnosis PCV via ICG Angiography evidence active leakage , active bleeding recent decreased vision . Baseline visual acuity well equal 20/200 use ETDRS Willing able comply clinic visit studyrelated procedure Provide sign informed consent Any history previous vitrectomy Previous cataract surgery within precede 2 month Day 0 Active infection conjunctivitis , keratitis , scleritis , endophthalmitis either eye Presence condition would jeopardize patient 's participation study Participation investigational trial within 30 day randomization involve treatment drug receive regulatory approval time study entry For TreatmentNaïve cohort : prior antiVEGF ( Macugen , Avastin , Lucentis , Eylea ) study eye For PreviousTreated cohort : prior antiVEGF ( Macugen , Avastin , Lucentis ) study eye within 30 day enrollment study For PreviousTreated cohort : prior Eylea study eye Known allergy component study drug Blood pressure &gt; 180/119 ( systolic 180 diastolic 110 ) . If blood pressure bring 180/110 antihypertensive treatment , patient eligible . Major surgery within 28 day prior randomization major surgery plan within next 12 month . Major surgery define surgical procedure extensive needle biopsy/aspiration placement central venous access device , removal/biopsy skin lesion , placement peripheral venous catheter Myocardial infarction , cardiac event require hospitalization , stroke , transient ischemic attack , treatment acute congestive heart failure within 6 month prior randomization Systemic antiVEGF proVEGF treatment within 3 month prior randomization Pregnant breastfeed woman Simultaneous participation another medical investigational trial Sexually active men* woman childbearing potential** unwilling practice adequate contraception study ( adequate contraceptive measure include stable use oral contraceptive prescription pharmaceutical contraceptive 2 menstrual cycle prior screen ; intrauterine device [ IUD ] ; bilateral tubal ligation ; vasectomy ; condom plus contraceptive sponge , foam , jelly , diaphragm plus contraceptive sponge , foam , jelly )</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>PCV</keyword>
</DOC>